

Christina Messiou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2661729/publications.pdf>

Version: 2024-02-01

118
papers

4,285
citations

147801

31
h-index

123424

61
g-index

120
all docs

120
docs citations

120
times ranked

4275
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis strategy of adipocytic soft-tissue tumors in adults: a consensus from European experts. <i>European Journal of Surgical Oncology</i> , 2022, 48, 518-525.	1.0	12
2	Starting CT-guided robotic interventional oncology at a UK centre. <i>British Journal of Radiology</i> , 2022, 95, 20220217.	2.2	5
3	Revisiting the Case of Sarah Newbury's Death from Mollities Ossium. <i>Cancer Investigation</i> , 2022, , 1-10.	1.3	0
4	A review on the added value of whole-body MRI in metastatic lobular breast cancer. <i>European Radiology</i> , 2022, 32, 6514-6525.	4.5	8
5	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSC) Database. <i>Sarcoma</i> , 2022, 2022, 1-13.	1.3	1
6	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. <i>Nature Ecology and Evolution</i> , 2022, 6, 88-102.	7.8	30
7	Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. <i>Cancer Research</i> , 2022, 82, A012-A012.	0.9	0
8	Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. <i>Cancer Research</i> , 2022, 82, PR002-PR002.	0.9	0
9	Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. <i>Magnetic Resonance Imaging</i> , 2021, 75, 60-64.	1.8	9
10	CT diagnosis of ilioinguinal lymph node metastases in melanoma using radiological characteristics beyond size and asymmetry. <i>BJS Open</i> , 2021, 5, .	1.7	1
11	Multiple Instance Learning with Auxiliary Task Weighting for Multiple Myeloma Classification. <i>Lecture Notes in Computer Science</i> , 2021, , 786-796.	1.3	4
12	MUK <i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. <i>BMJ Open</i> , 2021, 11, e046225.	1.9	18
13	Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. <i>British Journal of Radiology</i> , 2021, 94, 20200682.	2.2	8
14	Imaging response evaluation after neoadjuvant treatment in soft tissue sarcomas: Where do we stand?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103309.	4.4	14
15	The patient perspective in the era of personalized medicine: What about scanxiety?. <i>Cancer Medicine</i> , 2021, 10, 2943-2945.	2.8	17
16	Determining the incidence of interstitial pneumonitis and chronic kidney disease following full intensity haemopoietic stem cell transplant conditioned using a forward-planned intensity modulated total body irradiation technique. <i>Radiotherapy and Oncology</i> , 2021, 158, 97-103.	0.6	8
17	Real-world radiomics from multi-vendor MRI: an original retrospective study on the prediction of nodal status and disease survival in breast cancer, as an exemplar to promote discussion of the wider issues. <i>Cancer Imaging</i> , 2021, 21, 37.	2.8	13
18	Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8012-8012.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.. Journal of Clinical Oncology, 2021, 39, 8001-8001.	1.6	13
20	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. Radiology, 2021, 299, 494-507.	7.3	26
21	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open, 2021, 6, 100170.	4.5	65
22	Soft tissue and visceral sarcomas: ESMOâ€œEURACANâ€œGENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ†. Annals of Oncology, 2021, 32, 1348-1365.	1.2	381
23	CT-Based Pelvic T1-Weighted MR Image Synthesis Using UNet, UNet++ and Cycle-Consistent Generative Adversarial Network (Cycle-GAN). Frontiers in Oncology, 2021, 11, 665807.	2.8	17
24	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiology Imaging Cancer, 2021, 3, e210048.	1.6	22
25	Accelerating Whole-Body Diffusion-weighted MRI with Deep Learningâ€œbased Denoising Image Filters. Radiology: Artificial Intelligence, 2021, 3, e200279.	5.8	8
26	Updates and Ongoing Challenges in Imaging of Multiple Myeloma: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 217, 775-785.	2.2	9
27	Radiomics in Oncology: A Practical Guide. Radiographics, 2021, 41, 1717-1732.	3.3	139
28	Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. European Journal of Surgical Oncology, 2021, 47, 2595-2601.	1.0	3
29	Whole-body MRI: a practical guide for imaging patients with malignant bone disease. Clinical Radiology, 2021, 76, 715-727.	1.1	11
30	Descriptive analysis of MRI functional changes occurring during reduced dose radiotherapy for myxoid liposarcomas. British Journal of Radiology, 2021, 94, 20210310.	2.2	1
31	Overview of malignant soft-tissue sarcomas of the limbs. Clinical Radiology, 2021, 76, 940.e1-940.e16.	1.1	5
32	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	13.2	66
33	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	13.2	123
34	Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial. Blood, 2021, 138, 465-465.	1.4	8
35	Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial. Blood, 2021, 138, 2699-2699.	1.4	2
36	Imaging features of primary sites and metastatic patterns of angiosarcoma. Insights Into Imaging, 2021, 12, 189.	3.4	3

#	ARTICLE	IF	CITATIONS
37	Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. <i>European Radiology</i> , 2020, 30, 320-327.	4.5	18
38	MRI and PET/MRI in hematologic malignancies. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1325-1335.	3.4	28
39	Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. <i>Clinical Oncology</i> , 2020, 32, e27-e35.	1.4	12
40	CT imaging improves histopathological grading of retroperitoneal leiomyosarcomas. <i>European Journal of Surgical Oncology</i> , 2020, 46, 288-292.	1.0	8
41	Inter-observer agreement of baseline whole body MRI in multiple myeloma. <i>Cancer Imaging</i> , 2020, 20, 48.	2.8	6
42	Pictorial review of whole body MRI in myeloma: emphasis on diffusion-weighted imaging. <i>British Journal of Radiology</i> , 2020, 93, 20200312.	2.2	4
43	Improving real-world myeloma patient access to whole body MRI through "open access" knowledge sharing: The UK experience. <i>EJHaem</i> , 2020, 1, 361-363.	1.0	2
44	What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. <i>British Journal of Radiology</i> , 2020, 93, 20200562.	2.2	26
45	iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study. <i>Cancer Imaging</i> , 2020, 20, 79.	2.8	1
46	Robotic surgery for gastric gastrointestinal stromal tumors: A single center case series. <i>Journal of Surgical Oncology</i> , 2020, 122, 691-698.	1.7	7
47	Detection and Characterization of Musculoskeletal Cancer Using Whole-Body Magnetic Resonance Imaging. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 726-750.	0.7	7
48	Diffusion MRI: Applications Outside the Brain. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2020, 1, 637-663.	0.1	0
49	Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A New Era for Whole Body Imaging in Myeloma?. , 2019, , 73-85.		1
50	Diagnostic performance of MRI and histology in assessment of deep lipomatous tumours. <i>British Journal of Surgery</i> , 2019, 106, 1794-1799.	0.3	9
51	Supervised Machine-Learning Enables Segmentation and Evaluation of Heterogeneous Post-treatment Changes in Multi-Parametric MRI of Soft-Tissue Sarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 941.	2.8	22
52	PO-0869 Reducing pulmonary and renal toxicity in children receiving TBI with forward planned IMRT. <i>Radiotherapy and Oncology</i> , 2019, 133, S458.	0.6	0
53	The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. <i>Anticancer Research</i> , 2019, 39, 4891-4896.	1.1	13
54	Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. <i>British Journal of Radiology</i> , 2019, 92, 20180822.	2.2	6

#	ARTICLE	IF	CITATIONS
55	Utility of Multi-Parametric Quantitative Magnetic Resonance Imaging for Characterization and Radiotherapy Response Assessment in Soft-Tissue Sarcomas and Correlation With Histopathology. <i>Frontiers in Oncology</i> , 2019, 9, 280.	2.8	24
56	Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. <i>Anticancer Research</i> , 2019, 39, 347-351.	1.1	0
57	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). <i>Radiology</i> , 2019, 291, 5-13.	7.3	209
58	Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. <i>Anticancer Research</i> , 2019, 39, 6223-6230.	1.1	3
59	Imaging in myeloma with focus on advanced imaging techniques. <i>British Journal of Radiology</i> , 2019, 92, 20180768.	2.2	21
60	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-ESTBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	5.1	32
61	Imaging in retroperitoneal soft tissue sarcoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 25-32.	1.7	35
62	Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. <i>European Radiology</i> , 2018, 28, 1687-1691.	4.5	29
63	Perioperative Management of Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 118-124.	1.6	33
64	Quantitative Whole-Body Diffusion-Weighted MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 479-494.	1.1	19
65	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. <i>Medical Oncology</i> , 2018, 35, 138.	2.5	26
66	Whole-Body Imaging in Multiple Myeloma. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 509-525.	1.1	15
67	OC-0386: Incidence of pneumonitis and CKD following novel FP IMRT TBI conditioning for full intensity HSCT. <i>Radiotherapy and Oncology</i> , 2018, 127, S197-S198.	0.6	0
68	Surgical management of metastatic gastrointestinal stromal tumour. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1295-1300.	1.0	11
69	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. <i>Medical Oncology</i> , 2018, 35, 131.	2.5	14
70	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2298-2303.	1.3	21
71	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. <i>Acta Oncologica</i> , 2017, 56, 1013-1020.	1.8	29
72	Treatment of retroperitoneal sarcoma: current standards and new developments. <i>Current Opinion in Oncology</i> , 2017, 29, 260-267.	2.4	56

#	ARTICLE	IF	CITATIONS
73	The management of soft tissue tumours of the abdominal wall. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1647-1655.	1.0	11
74	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. <i>Radiology</i> , 2017, 284, 88-99.	7.3	45
75	Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1191-1198.	1.0	101
76	Whole-Body MRI: Current Applications in Oncology. <i>American Journal of Roentgenology</i> , 2017, 209, W336-W349.	2.2	89
77	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSC). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	1.2	274
78	Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 113-117.	4.2	31
79	Paratesticular Sarcoma: Typical Presentation, Imaging Features, and Clinical Challenges. <i>Urology</i> , 2017, 100, 163-168.	1.0	19
80	A molecular signature predictive of clinical outcome following pazopanib therapy in advanced soft tissue sarcoma. <i>Annals of Oncology</i> , 2017, 28, x149.	1.2	2
81	Elastofibroma dorsii: The clunking tumour that need not cause alarm. <i>Annals of the Royal College of Surgeons of England</i> , 2016, 98, 208-211.	0.6	8
82	Endometriosis of Extra-Abdominal Soft Tissues. <i>International Journal of Surgical Pathology</i> , 2016, 24, 497-503.	0.8	8
83	Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma. <i>Haematologica</i> , 2016, 101, e142-e144.	3.5	25
84	PO-0765: Management of primary cardiac and great vessel sarcomas, The RMH experience 2000-2015. <i>Radiotherapy and Oncology</i> , 2016, 119, S358-S359.	0.6	0
85	Selective marginal resections in the management of aggressive angiomyxomas. <i>Journal of Surgical Oncology</i> , 2016, 114, 828-832.	1.7	6
86	Validating a robust doubleâ€quantumâ€filtered ¹ H MRS lactate measurement method in highâ€grade brain tumours. <i>NMR in Biomedicine</i> , 2016, 29, 1420-1426.	2.8	10
87	Desmoplastic Small Round Cell Tumor. <i>International Journal of Surgical Pathology</i> , 2016, 24, 672-684.	0.8	50
88	Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?. <i>Leukemia</i> , 2016, 30, 1446-1448.	7.2	125
89	Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer â€ Soft Tissue and Bone Sarcoma Group (EORTC â€) Tj ETQq1 1 0.784314 rgBT emphasis on magnetic resonance imaging. <i>European Journal of Cancer</i> . 2016, 56, 37-44.	2.8	48
90	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancerâ€Soft Tissue and Bone Sarcoma Group (EORTCâ€STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016, 53, 84-95.	2.8	99

#	ARTICLE	IF	CITATIONS
91	Cyclist's nodule: no smooth ride. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213087.	0.5	5
92	3401 Absence of progression, not extent of remission defines prognosis in soft tissue sarcoma - an analysis of the EORTC 62012 study. <i>European Journal of Cancer</i> , 2015, 51, S688.	2.8	2
93	Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. <i>British Journal of Surgery</i> , 2015, 102, 965-971.	0.3	72
94	p16 Expression in Fat Necrosis. <i>International Journal of Surgical Pathology</i> , 2015, 23, 544-548.	0.8	14
95	Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience. <i>Clinical Sarcoma Research</i> , 2015, 5, 5.	2.3	69
96	Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. <i>Clinical Radiology</i> , 2015, 70, 614-621.	1.1	54
97	Low-dose whole-body CT for staging multiple myeloma. <i>Clinical Radiology</i> , 2015, 70, S7.	1.1	2
98	Desmoid-type fibromatosis. <i>Clinical Radiology</i> , 2015, 70, 1038-1045.	1.1	67
99	Whole body diffusion weighted ¹H MRI - a new view of myeloma. <i>British Journal of Haematology</i> , 2015, 171, 29-37.	2.5	80
100	Optimal management of primary retroperitoneal sarcoma: an update. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 565-579.	2.4	31
101	Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma. <i>Case Reports in Medicine</i> , 2014, 2014, 1-5.	0.7	7
102	Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values. <i>Skeletal Radiology</i> , 2014, 43, 205-208.	2.0	20
103	Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. <i>European Journal of Cancer</i> , 2014, 50, 2519-2531.	2.8	134
104	Soft-tissue masses in the abdominal wall. <i>Clinical Radiology</i> , 2014, 69, e422-e431.	1.1	32
105	Whole-Body Diffusion-weighted MR Imaging for Assessment of Treatment Response in Myeloma. <i>Radiology</i> , 2014, 271, 785-794.	7.3	178
106	Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: A report of the U.K. Managed Access Program.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10551-10551.	1.6	2
107	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. <i>Sarcoma</i> , 2013, 2013, 1-6.	1.3	54
108	Assessing response of myeloma bone disease with diffusion-weighted MRI. <i>British Journal of Radiology</i> , 2012, 85, e1198-e1203.	2.2	128

#	ARTICLE	IF	CITATIONS
109	Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity. <i>Radiology</i> , 2012, 265, 426-436.	7.3	51
110	Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. <i>European Radiology</i> , 2011, 21, 1713-1718.	4.5	143
111	Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. <i>European Radiology</i> , 2011, 21, 2169-2177.	4.5	90
112	The CT flare response of metastatic bone disease in prostate cancer. <i>Acta Radiologica</i> , 2011, 52, 557-561.	1.1	55
113	Metastatic Ovarian and Primary Peritoneal Cancer: Assessing Chemotherapy Response with Diffusion-weighted MR Imagingâ€”Value of Histogram Analysis of Apparent Diffusion Coefficients. <i>Radiology</i> , 2011, 261, 182-192.	7.3	211
114	Metastasis imaging: Current concepts and future challenges. <i>Cancer Biomarkers</i> , 2011, 7, 171-172.	1.7	2
115	Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring. <i>Cancer Biomarkers</i> , 2010, 6, 21-32.	1.7	24
116	Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2548-2548.	1.6	1
117	Abstract A102: Firstâ€”man, firstâ€”class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CCâ€”chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCPâ€”1) in patients with advanced solid tumors. , 2009, , .		0
118	Radiomic Features From Diffusion-Weighted MRI of Retroperitoneal Soft-Tissue Sarcomas Are Repeatable and Exhibit Change After Radiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4